Drug
Monoclonal Antibody Rav12
Monoclonal Antibody Rav12: highest development phase Phase 1, developed by MacroGenics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| monoclonal antibody RAV12 NCT00101972 | Phase 1 | Cancer |
Latest
No recent events.
Follow Monoclonal Antibody Rav12 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.